

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – July 11, 2018 @ 4:00p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

A. June 13, 2018 DUR Minutes – Vote

B. June 13, 2018 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Action Item – Update on Medication Coverage Authorization Unit/SoonerCare Opioid Initiative Update – See Appendix B

A. Medication Coverage Activity for June 2018

B. Pharmacy Help Desk Activity for June 2018

C. SoonerCare Opioid Initiative Update – Vote

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Crystvita[®] (Burosumab-twza) – See Appendix C

A. Introduction

B. Market News and Updates

C. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Imfinzi[®] (Durvalumab) and to Update the Current Lung Cancer Medications Prior Authorization Criteria – See Appendix D

A. Introduction

B. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Erleada[™] (Apalutamide) and Yonsa[®] (Abiraterone) – See Appendix E

A. Introduction

B. Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Cotempla XR-ODT[™] [Methylphenidate Extended-Release (ER) Orally Disintegrating Tablet (ODT)], Mydayis[®] (Amphetamine/Dextroamphetamine ER Capsule), and Adzenys ER[™] (Amphetamine ER Suspension) – See Appendix F

A. Introduction

B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Baclofen 5mg Tablet, Esomep-EZS™ (Esomeprazole Kit), Lyrica® CR (Pregabalin Extended-Release), Restasis MultiDose® (Cyclosporine 0.05% Ophthalmic Emulsion), Sinuva™ (Mometasone Furoate Sinus Implant), Xepi™ (Ozenoxacin 1% Cream), Xhance™ (Fluticasone Propionate Nasal Spray), and ZTlido™ (Lidocaine 1.8% Topical System) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

10. Action Item – Annual Review of Atopic Dermatitis (AD) Medications – See Appendix H

- A. Current Prior Authorization Criteria
- B. Utilization of AD Medications
- C. Prior Authorization of AD Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of AD Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

11. Action Item – Annual Review of Botulinum Toxins – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Botulinum Toxins
- C. Prior Authorization of Botulinum Toxins
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Botulinum Toxins

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

12. Annual Review of Opioid Analgesics and Opioid Medication Assisted Treatment (MAT) Medications and 30-Day Notice to Prior Authorize Apadaz® [Benzhydrocodone/Acetaminophen (APAP)], Lucemyra™ (Lofexidine), and Sublocade™ [Buprenorphine Extended-Release (ER) Injection] – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Opioid Analgesics and MAT Medications
- C. Prior Authorization of Opioid Analgesics and MAT Medications
- D. Market News and Updates
- E. Apadaz® (Benzhydrocodone/APAP Tablets) Product Summary
- F. Lucemyra™ (Lofexidine Tablets) Product Summary
- G. Sublocade™ [Buprenorphine ER Injection] Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of Opioid Analgesics
- J. Utilization Details of MAT Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Jynarque™ (Tolvaptan) – See Appendix K

- A. Introduction
- B. Market News and Updates
- C. Jynarque™ (Tolvaptan) Product Summary
- D. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

14. Annual Review of Vimizim® (Elosulfase Alfa) – See Appendix L

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Vimizim® (Elosulfase Alfa)
- D. Prior Authorization of Vimizim® (Elosulfase Alfa)
- E. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

15. Annual Review of Brineura® (Cerliponase Alfa) – See Appendix M

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Brineura® (Cerliponase Alfa)
- D. Prior Authorization of Brineura® (Cerliponase Alfa)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

16. Annual Review of Radicava® (Edaravone) – See Appendix N

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Radicava® (Edaravone)
- D. Prior Authorization of Radicava® (Edaravone)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Non-Presentation; Questions Only:

17. Industry News and Updates – See Appendix O

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

18. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix P

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

19. Future Business* (Upcoming Product and Class Reviews)

No meeting scheduled for August.

- A. Antihyperlipidemics
- B. Fabrazyme® (Agalsidase Beta)
- C. Growth Hormone
- D. Butalbital Medications
- E. Synagis® (Palivizumab)
- F. Breast Cancer Medications
- G. Sickle Cell Medications

**Future business subject to change.*

20. Adjournment